CV Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CV Therapeutics, Inc.
First licensing agreement for MeMed adds its immune system-based protein signature test to DiaSorin’s LIAISON test menu.
Four key Asian markets witnessed nearly 200 life science company listings over the past 10 years, with China dominating the scene and expected to stay ahead, along with Hong Kong, for the foreseeable future. But India could prove a new contender over time as firms move up the value chain, a new report shows.
Focused primarily on developing diagnostic tests to determine whether patients will respond to a drug, Scipher is also using the data from its artificial intelligence process to drive R&D partnerships with drug developers.
CinnaGen has revealed clinical trial results suggesting that its ReciGen interferon beta-1a product in combination with concomitant antiviral therapy can be “a new safe and effective” treatment option for COVID-19 patients, “critical for the expected second wave of the pandemic.”